Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
P/E ratio for Cassava Sciences, Inc. (SAVA)
P/E ratio as of 2023: -9.71
According to Cassava Sciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.71. At the end of 2022 the company had a P/E ratio of -16.39.
P/E ratio history for Cassava Sciences, Inc. from 1999 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -9.71 |
| 2022 | -16.39 |
| 2021 | -54.15 |
| 2020 | -30.41 |
| 2019 | -21.33 |
| 2018 | -1.38 |
| 2017 | -2.20 |
| 2016 | -1.75 |
| 2015 | -5.66 |
| 2014 | -7.42 |
| 2013 | 6.93 |
| 2012 | -35.19 |
| 2011 | -64.22 |
| 2010 | -23.94 |
| 2009 | -65.19 |
| 2008 | 16.30 |
| 2007 | 23.05 |
| 2006 | 63.49 |
| 2005 | -9.65 |
| 2004 | -7.11 |
| 2003 | -9.48 |
| 2002 | -4.06 |
| 2001 | -16.18 |
| 2000 | -11.60 |
| 1999 | -16.26 |